Clinical trials report. Chronic kidney disease: blood pressure, treatment goals, and cardiovascular outcomes

Affiliations

Comment

Matthew R Weir. Curr Hypertens Rep. 2003 Oct.

. 2003 Oct;5(5):405-7.

doi: 10.1007/s11906-003-0086-x.

¹ Division of Nephrology N3W143, University of Maryland Hospital, 22 S. Greene Street, Baltimore, MD 21201, USA. mweir@medicine.umaryland.edu

No abstract available

Comment on

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.